Is ValiRx PLC halal to invest in?

According to Musaffa's Shariah screening methodology, ValiRx PLC (VAL.L) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is ValiRx PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ValiRx PLC using these criteria to determine its compliance status.

Can Muslims buy shares of ValiRx PLC?

Muslim investors may consider investing in ValiRx PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ValiRx PLC classified as NOT HALAL?

Musaffa determines the Shariah status of ValiRx PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ValiRx PLC updated?

The Shariah compliance status of ValiRx PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ValiRx PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ValiRx PLC?

You can check the latest Shariah compliance status of ValiRx PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ValiRx PLC VAL.L

GBX0.20 GBX0.02 (6.98%) 1D

Last Updated: May 15, 12:00 AM·LSE

VAL.L Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: January 26, 2026

Report Source: 2025 2nd Quarter Report

Analyst's Ratings for ValiRx PLC (VAL.L)

Based on 9 analysts giving stock ratings to ValiRx PLC in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

ValiRx PLC. Stock Analysis VAL.L

United Kingdom Health Care Nano Cap Report: Q2, 2025

ValiRx Plc is a life science company. The company is headquartered in Nottingham, Nottinghamshire and currently employs 14 full-time employees. The company went IPO on 2000-02-28. The firm provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The firm selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

Key Statistics of ValiRx PLC (VAL.L)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

GBX0.19GBX0.23

Today's Open

GBX0.22

Volume

41.90M

P/E Ratio (TTM)

52 Week Range

GBX0.19GBX0.88

Market Cap

207.98M

Avg. Volume

1.07M

Dividend Yield

Financial Metrics & Statements of ValiRx PLC (VAL.L)

FAQ's for ValiRx PLC (VAL.L)

According to Musaffa’s Shariah screening methodology, ValiRx PLC (VAL.L) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.